Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes
How to cite: Ozbay, M. F.; Harputluoglu, H.; Karaca, M.; Tekin, O.; Şendur, M. A. N.; Kaplan, M. A.; Sahin, B.; Geredeli, C.; Teker, F. T.; Tural, D.; Saglam, S.; Çil, T.; Bilici, A.; Erol, C.; Kalkan, Z.; Bayram, E.; Selvi, O.; Gültürk, İ.; Göksu, S. S.; Tatlı, A. M. Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes. Preprints 2024, 2024102285. https://doi.org/10.20944/preprints202410.2285.v1 Ozbay, M. F.; Harputluoglu, H.; Karaca, M.; Tekin, O.; Şendur, M. A. N.; Kaplan, M. A.; Sahin, B.; Geredeli, C.; Teker, F. T.; Tural, D.; Saglam, S.; Çil, T.; Bilici, A.; Erol, C.; Kalkan, Z.; Bayram, E.; Selvi, O.; Gültürk, İ.; Göksu, S. S.; Tatlı, A. M. Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes. Preprints 2024, 2024102285. https://doi.org/10.20944/preprints202410.2285.v1
Abstract
Keywords
Subject
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)